Trial Profile
Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Anaemia; Leucopenia; Neutropenia; Pancytopenia; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 5 Dec 2023 to 30 Nov 2023.
- 01 Dec 2023 Status changed from recruiting to discontinued due to no enrollment.
- 29 Nov 2023 Planned initiation date (estimated date for recruitment of the first subject) changed to 05 Dec 2023.